ICN 16064
Alternative Names: Anti-CD28 oligonucleotide; Antisense 16064; Antisense oligonucleotide 16064Latest Information Update: 19 Jul 2018
At a glance
- Originator Valeant Pharmaceuticals International
- Class Antipsoriatics; Nucleotides
- Mechanism of Action CD28 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 07 Jun 2000 Preclinical development for Psoriasis in USA (Unknown route)